Volume 7, Issue 2 (12-2020)                   vacres 2020, 7(2): 101-106 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Amopour Bahnamiry M, Kaghazian H, Mousavi-Nasab S D, Aghasadeghi M R, Bahramali G. Engineering and Development of VP4-VP7 Rotavirus Fusion Protein in Pichia pastoris. vacres. 2020; 7 (2) :101-106
URL: http://vacres.pasteur.ac.ir/article-1-263-en.html
Department of Research and Development, Production and Research Complex, Pasteur Institute of Iran, Tehran, Iran
Abstract:   (274 Views)
Introduction: Vaccination is the most effective measure to prevent Rotavirus infection in children under five years of age. The most important targets of neutralizing and protective antibodies against this virus are VP4 and VP7 proteins of Rotavirus. Today, the recombinant protein produced in yeast plays an important role in producing highly effective and cost-effective vaccines. Methods: The effect of different linkers, including flexible and rigid, were evaluated on the stability and immunogenicity of the protein via in silico assays. A suitable linker was selected and expressed in Pichia pastoris yeast. Prediction and validation were carried out using bioinformatics tools, including Expasy's ProtPara, Phyre2 online server, I-TASSER server, ElliPro. Moreover, an appropriate linker was selected for cloning into pPICZα and expression in P. pastoris. Results: The results showed that as a flexible linker, (GGGGS)3 was the best structure to provide stability for VP4-VP7 target fusion protein. The produced recombinant protein was stable after the expression. Conclusion: These in silico results and expression data on P. pastoris suggested that VP4–(GGGGS)3-VP7 construct can potentially serve as a potent immunogenic candidate for recombinant Rotavirus vaccines.
Full-Text [PDF 437 kb]   (134 Downloads)    
Type of Study: Research | Subject: Humanand veterinary vaccines
Received: 2021/09/25 | Accepted: 2020/12/1 | Published: 2021/09/26

Add your comments about this article : Your username or Email:

Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2022 All Rights Reserved | Vaccine Research

Designed & Developed by : Yektaweb

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.